In this article:
- Company Overview
- Stock Performance
- Market Position and Sector
- Governance and Leadership
- Key Financial Data
- FAQ
- Conclusion
- Disclaimer
- Official Announcement
Company Overview
ICU Medical, Inc., headquartered in San Clemente, California, designs, manufactures, and sells medical devices for infusion therapy and critical care applications globally. Established in 1984, the company has expanded its portfolio to include brands such as MicroClave, Neutron catheter devices, SwabCap disinfecting caps, and infusion pumps under Plum 360 and LifeCare PCA. Its comprehensive product offerings cater to acute care hospitals, wholesalers, ambulatory clinics, and home health care providers. With approximately 15,000 employees, ICU Medical remains a notable player in the medical instruments and supplies industry.
Stock Performance
ICU Medical’s stock is listed on the NASDAQ Global Select Market under the ticker symbol ICUI. As of the latest market update, the share price stands at USD 121.945, reflecting a change of +0.565 or +0.465% from the previous close. The price range over the year has been between USD 107 and USD 196.26, indicating volatility within a significant trading band.
The daily trading volume is 6,107 compared to an average volume of 290,759 shares. This low current volume may suggest reduced short-term liquidity. Investors often watch for volume spikes that may signal increased market activity or emerging trends in investor sentiment.
Market Position and Sector
With a market capitalization of approximately USD 3.01 billion, ICU Medical falls within the mid-cap category. Operating in the healthcare sector and specifically within medical instruments and supplies, the company addresses critical needs across infusion therapy, IV medication safety, and hemodynamic monitoring. The healthcare sector is characterized by resilience during economic cycles, but it still faces regulatory and competitive challenges.
ICU Medical’s broad international presence positions it for opportunities in both established and emerging markets. Product diversification within essential healthcare solutions contributes to its competitive posture.
Governance and Leadership
Vivek Jain serves as the CEO. Leadership stability is a notable aspect for stakeholders evaluating long-term strategic execution. Under Jain’s direction, the firm has focused on integrating product innovation with compliance in manufacturing quality standards. The governance strategy emphasizes meeting the needs of diverse healthcare delivery systems, supporting both acute and alternate site facilities.
Key Financial Data
- Price: USD 121.945
- Market Cap: USD 3.01 billion
- Dividend: The company has not paid a dividend in recent periods. This may indicate reinvestment priorities over shareholder payouts.
- 52-week Range: USD 107 – USD 196.26
- Volume: 6,107 shares
- Average Volume: 290,759 shares
The absence of dividends may signal to investors that ICU Medical is focused on growth, possibly through R&D and market expansion. The wide price range illustrates the dynamic nature of share valuation over the year, both presenting opportunities and requiring caution.
Trading Details
- Exchange: NASDAQ Global Select
- ISIN: US44930G1076
- CUSIP: 44930G107
- CIK: 0000883984
- IPO Date: March 31, 1992
- Currency: USD
These identifiers are essential for investors tracking the security and ensuring accurate transactional data across national and international trading systems.
FAQ
- Does ICU Medical pay dividends? Currently no dividend payments have been issued.
- Where is ICU Medical headquartered? In San Clemente, California, United States.
- How many full-time employees does the company have? Around 15,000.
- What is the primary industry? Medical instruments and supplies.
- When was the IPO? March 31, 1992.
Conclusion
ICU Medical, Inc. presents a stable mid-cap healthcare investment with a focus on critical medical devices and infusion therapy solutions. Current trading shows modest fluctuation, with significant potential in its market sector driven by a clear global presence and diversified product portfolio. Investors should note the lack of dividend payments and evaluate the company based on growth and innovation prospects.
Disclaimer
This article is for informational purposes only and does not constitute financial advice. Investors should perform their own due diligence before making investment decisions.
Official Announcement
For full information about the company, see the link below.